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Background: Metabolic complications represent a common and serious problem
associated with HIV infection and combined Antiretroviral Therapy (cART). Alterations
in body fat distribution are associated with significantly increased risks of (i) metabolic
derangements, (ii) cardiovascular pathologies, and (iii) insulin resistance. A case control
study showed that in subcutaneous adipose tissue from HIV-infected patients on cART
presenting lipodystrophy (LS), the levels of miRNA-218 were upregulated and those of
lipin-1, a putative target gene of miRNA-218, were downregulated compared with HIV-
negative subjects. Lipin-1 is one of the most important factors linked to development of
LS. Lipin-1, by controlling PPARγ2, regulates the expression of specific genes, such as
that of glucose transporter type 4 (GLUT-4), required for maturation and maintenance of
adipocytes.
Objectives: To determine whether lopinavir/ritonavir (LPV/RTV) can modulate
lipogenesis in adipocytes affecting miRNA-218 and lipin-1 mRNA expression, and to
investigate the functional link between miRNA-218 and GLUT-4 mRNA expression.
Methods: Differentiated 3T3-L1 cells were treated with various combinations of
LPV/RTV, followed by measurements of cell viability, lipid accumulation, lipin-1 and
GLUT-4 mRNA and miRNA-218 levels. Transfection of anti-miR-218 or a miRNA-218
mimic were used to investigate the role of miRNA-218 in lipogenesis.
Results: LPV/RTV treatment of 3T3-L1 cells did not affect the viability of differentiated
3T3-L1 cells, but caused (i) a significant decrease of lipid accumulation, (ii) an
overexpression of miRNA-218, and (iii) a reduction of lipin-1 and GLUT-4 mRNA levels.
The anti-miR-218 transfection of 3T3-L1 cells significantly ameliorated the adipogenic
dysfunction and restored mRNA levels of lipin-1 and GLUT-4 consequent to LPV/RTV
treatment. By contrast, 3T3-L1 cells transfected with a specific miRNA-218 mimic
showed (i) an overexpression of miRNA-218, (ii) a reduced cellular lipid fraction, and
(iii) decreased levels of mRNA for lipin-1 and GLUT-4.
Frontiers in Pharmacology | www.frontiersin.org 1 April 2019 | Volume 10 | Article 461
fphar-10-00461 April 27, 2019 Time: 15:34 # 2
Bresciani et al. miRNA-218 Regulates Lipin-1 mRNA Levels
Conclusion: 3T3-L1 cells, treated with LPV/RTV, show altered lipid content due to
increased miRNA-218 levels, which affects lipin-1 mRNA. Moreover, increased miRNA-
218 levels were inversely correlated with changes in GLUT-4 expression, which suggests
a role for miRNA-218 in mediating the insulin resistance consequent to cART.
Keywords: HIV protease inhibitors, lipodystrophy, miRNA, adipocyte, insulin resistance
INTRODUCTION
Metabolic syndrome is a serious consequence of combined
Antiretroviral Therapy (cART). HIV-associated metabolic
syndrome is often accompanied by lipodystrophy (LS), the
redistribution of body fat with loss of subcutaneous adipose
tissue in face, limbs and buttocks, concomitant with fat
accumulation in the trunk and in the intra-abdominal and inter-
scapular regions. These morphological alterations are associated
with metabolic dysfunctions including (i) insulin-resistance, (ii)
hypercholesterolemia, and (iii) hypertriglyceridemia (Reinsch
et al., 2012), all of which predispose the individual to increased
risks of developing cardiovascular diseases as well as type II
diabetes (Costa and Almeida, 2015).
The causes of HIV-associated metabolic syndrome and LS
are multiple, and poorly understood. HIV itself promotes LS, by
generating a local inflammation of adipose tissue (Caron-Debarle
et al., 2010). Similarly, the nucleoside reverse transcriptase
inhibitors (NRTIs) and protease inhibitors (PIs) (Minami
et al., 2011; Manente et al., 2012) used in cART, primarily
contribute to the development of metabolic dysfunctions
by promoting lipohypertrophy and lipoatrophy, respectively,
ultimately manifested in an imbalance of adipose tissue functions
(Gibellini et al., 2012). Based on the most current guidelines of
United States Department of Health and Human Services for Use
of Antiretroviral Agents in HIV-infected patients, PIs are still a
key component of ART regimens, due the ability to maintain viral
load suppression, and will continue to be important drugs for the
foreseeable future. In this context, lopinavir (LPV) co-formulated
with ritonavir (RTV) in a ratio of 4:1, respectively, represent a
drug association frequently associated with metabolic syndrome,
that could predispose to fat redistribution, and development of
cardiovascular events (Croxtall and Perry, 2010).
Recently, it has been reported that dysregulation of microRNA
(miRNA) biogenesis may play a role in the onset of HIV-
associated metabolic syndrome and LS (Xu and Sun, 2015).
MiRNAs are small non-coding RNAs of about 20-nucleotides
in length, regulating gene expression at the posttranscriptional
level by binding to the target mRNA, leading either to its
degradation or to translational repression (Bartel, 2004). Several
miRNAs, i.e., miR-27, miR-130, miR-146b, and miR195a, are
involved in the regulation of adipogenesis with a promoting or
suppressing role (Lin et al., 2009; Lee et al., 2011; Ahn et al.,
2013; Yun et al., 2015), important for maintaining homeostasis
of adipose tissue. In subcutaneous adipocytes of HIV-infected
patients treated with cART, some miRNAs, including miRNA-
218, are upregulated (Squillace et al., 2014). Lipin-1 is among
miRNA-218 putative target genes (Squillace et al., 2014), as
suggested by bioinformatics analysis and publicly available
algorithms that are commonly used to predict downstream
targets in microRNA database (Squillace et al., 2014; Han et al.,
2015). Lipin-1 encodes a protein with a double function: it is
a phosphatidate phosphatase, involved in triglycerides synthesis,
and a transcriptional coactivator (Chen et al., 2015) necessary for
adipogenesis and the appropriate function of mature adipocytes
(Koh et al., 2008). A null mutation in the lipin-1 gene leads
to lipodystrophy in mice, and is characterized by (i) loss of
adipose tissue, (ii) deficiency in adipocyte differentiation, and (iii)
eventually to insulin resistance and circulating hyperlipidemia
(Peterfy et al., 2001). Expression of lipin-1 is also inversely
correlated with insulin sensitivity: indeed, reduced levels of lipin-
1 in mature adipocytes are associated with reduced expression
of glucose transporter 4 (GLUT-4) (van Harmelen et al., 2007).
Lipin-1 activity is mediated by a direct interaction with PPARγ2,
which in turn controls GLUT-4 expression (van Harmelen et al.,
2007). The inverse correlation between lipin-1 mRNA levels
and miRNA-218 expression in subcutaneous fat samples of
HIV-positive subjects suggests a negative regulation on lipin-1
expression by miRNA-218 (Squillace et al., 2014).
In this study we used a simplified model of in vitro
lipodystrophy, consisting of differentiated 3T3-L1 cells treated
with a LPV/RTV co-formulation, in order to investigate the
relationship between miRNA-218 and the target gene predicted
by bioinformatics analysis. In this model, characterized by
decreased levels of lipin-1 mRNA expression and increased levels
of miRNA-218, we demonstrate by, respectively, loss and gain of
function experiments that miRNA-218 targets the lipin-1 gene,
and negatively regulates the mRNA levels of GLUT-4.
MATERIALS AND METHODS
Cell Culture
The murine 3T3-L1 cell line was obtained from the American
Type Culture Collection (Manassas, VA, United States) and
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% newborn calf serum (NCS) (Euroclone,
Pero, Italy), 100 IU/ml penicillin, and 100 µg/ml streptomycin
(Invitrogen, Carlsbad, CA, United States). Cells were maintained
at 37◦C in 5% CO2. Sub-confluent cells were induced to
differentiate (day 0) by incubation with Induction Medium
(DMEM supplemented with 10% fetal bovine serum (FBS,
EuroClone, Pero, Italy), 0.5 mM 3-isobutyl-1-methylxanthine,
1 µM dexamethasone and 10 µg/ml insulin) for 2 days. The
culture medium was then replaced every 48 h with Insulin
Medium (DMEM supplemented with 10% FBS and 10 µg/ml
insulin) until the adipocytes reached differentiation. In all the
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experiments, mature adipocytes were used when 80% of cells
appeared differentiated (8–10 total days). Unless otherwise
specified, all other reagents were from Sigma-Aldrich (St Louis,
MO, United States).
Antiretroviral Drugs
Lopinavir (LPV) and ritonavir (RTV) were purchased from
Santa Cruz Biotechnology (Dallas, TX, United States). These two
PIs were dissolved in dimethyl sulfoxide (DMSO) and stored
at −20◦C, then diluted into culture media on the day of the
experiment. Fully differentiated 3T3-L1 cells were treated with
PIs for 48 h. LPV and RTV were used in combination at a 4:1
(LPV:RTV) ratio, as previously reported in studies on 3T3-L1
cells and human pre-adipocytes in vitro (Gallego-Escuredo et al.,
2010; Zha et al., 2013), and consistent to the therapeutic regimen
(Kumar et al., 2004). The final LPV:RTV doses were chosen on the
basis of dose-response experiments (data not shown) and were
12 µM:3 µM and 16 µM:4 µM.
Cells Viability Assays
Differentiated 3T3-L1 cells were seeded in 96-well culture plates
and exposed to PIs for 48 h. At the end of treatment, cells
were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT, 5 mg/ml) at 37◦C for 3 h. The
formazan dye crystals were solubilized with 200 µl isopropanol.
Absorbance was measured using a VICTOR3 spectrophotometer
(Perkin Elmer Italia, Milano, Italy) at 570 nm wavelength.
Experiments were repeated at least three times in separate days.
Oil Red O Staining
3T3-L1 cells were plated in 24-well culture plates and exposed for
48 h to LPV:RTV combinations. At the end of the treatment, cells
were washed twice with PBS and fixed with 10% formaldehyde
in PBS for 90 min at 37◦C. The fixative was removed, each well
was washed twice with sterile water and stained with 200 µL of
oil red O (ORO) solution for 2 h at 37◦C. After the staining,
cells were washed with sterile water and incubated with 200 µL
of isopropanol; the absorbance was measured at 520 nm with a
VICTOR3 spectrophotometer.
Studies of Loss and Gain of Function:
miRNA Inhibitor and miRNA Mimic
Transfection Assays
MirVana R© miRNA inhibitor hsa-miR-218-5p, mirVana R© miRNA
mimic hsa-miR-218-5p and mirVana R© Negative Control #1 were
purchased from Ambion R© (Thermo Fisher Scientific, Waltham,
MA, United States). Fully differentiated 3T3-L1 cells were
treated with LPV:RTV and transfected with one of synthetic
miRNAs using Lipofectamine RNAiMAX (Invitrogen, Carlsbad,
CA, United States) according to the manufacturer’s protocol; 24 h
after the transfection, culture medium was replaced with fresh
culture medium. The effects of transfection of miRNA inhibitor
or miRNA mimic or drug treatments, were evaluated after 48 h
by ORO and real-time PCR. To ascertain the success of miRNA
inhibitor transfection, 3T3-L1 cells were also transfected with
mirVana R© miRNA inhibitor let-7 Positive Control (Ambion R©).
This miRNA inhibitor blocks miRNA let-7, an endogenous
miRNA that usually down-regulates HMGA-2 gene expression.
The levels of HMGA-2 mRNA were evaluated by real-time PCR.
Real-Time PCR
Total RNA from fully differentiated and LPV:RTV treated 3T3-
L1 cells was isolated with TRIzol (EuroClone, Pero, Italy)
and quantified using a Nanodrop spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, United States). RT reaction
was performed using either iScriptTM cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, United States) for lipin-1 and GLUT-4
mRNA expression (360 ng of total RNA), or TaqMan MicroRNA
Reverse Transcription kit (Applied Biosystems, Thermo Fisher
Scientific, Waltham, MA, United States) for miRNAs expression
(10 ng of total RNA), according to the manufacturer’s
instructions. Real-Time qPCR was performed using Taqman
probes (Mm00550511_m1 for lipin-1, Mm00436615_m1 for
GLUT-4, and assay 000521 for miRNA-218) and iTaq Universal
Probe Supermix 2X (Bio-Rad, Hercules, CA, United States) in
a 7900HT Fast Real-Time PCR System (Applied Biosystems,
Thermo Fisher Scientific, Waltham, M, United States). The
expressions of lipin-1 and GLUT-4 were normalized for β-actin,
and that of miRNA-218 for U6 (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA, United States), respectively.
Statistical Analysis
Statistical analysis was performed using MATLAB (version
R2010b; Mathworks). Analysis of variance (One Way ANOVA)
was followed by Tukey-Kramer t-test. All results are expressed as
mean± standard error of the mean (SEM). A p-value of less than
0.05 was considered significant.
RESULTS
Lopinavir:Ritonavir Treatment Does Not
Affect 3T3-L1 Adipocytes Viability
Since PIs, including lopinavir and ritonavir, could affect adipose
cell differentiation and replication, we used the MTT assay to
ascertain whether different combinations of LPV:RTV could
induce cell-toxicity and affect the viability of 3T3-L1 cells.
Fully differentiated 3T3-L1 cells were exposed to two different
combinations of LPV:RTV (12 µM:3 µM and 16 µM:4 µM);
under both conditions, drug treatments did not significantly
reduced cell viability compared to vehicle-treated cells (Figure 1).
Lopinavir:Ritonavir Treatment Alters
Lipid Accumulation in Mature Adipocytes
In order to verify whether mature 3T3-L1 adipocytes are sensitive
to PIs treatment and could represent a useful in vitro model
to reproduce the adipose tissue abnormalities caused by PIs
regimens, the effects of LPV:RTV treatment on intracellular
lipid accumulation were evaluated. ORO staining showed that
exposure of mature adipocytes for 48 h to both LPV:RTV
dose combinations caused a significant reduction of lipid
accumulation compared to vehicle treated cells (−13.2% for
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FIGURE 1 | Effect of LPV:RTV treatment on viability of differentiated 3T3-L1
cells. Fully differentiated 3T3-L1 cells were treated for 48 h with LPV:RTV
(12 µM:3 µM, 16 µM:4 µM) or with vehicle alone. Absorbance was measured
at 570 nm. The values of absorbance were expressed relatively to absorbance
measured in the vehicle group. Results are expressed as mean ± SEM and
represent the mean of 18 determinations per group, obtained in three
independent experiments.
12 µM:3 µM and−14.5% for 16 µM:4 µM; p< 0.05 and p< 0.01
vs. vehicle, respectively) (Figures 2A,B).
Effect of Lopinavir:Ritonavir Treatment
on Lipin-1 mRNA Expression and
miRNA-218 Expression in Mature 3T3-L1
Adipocytes
Bioinformatic analysis showed that one of the predicted genes
regulated by miRNA-218 is lipin-1. In order to define more
precisely the inverse correlation between miRNA-218 and its
putative target gene, lipin-1, mature 3T3-L1 adipocytes were
treated with LPV:RTV (12 µM:3 µM, 16 µM:4 µM) for
48 h; lipin-1 mRNA levels and miRNA-218-5p expression
were evaluated by real-time PCR. Lipin-1 mRNA levels were
significantly lower after treatment with LPV:RTV compared to
vehicle-treated cells (−51% for 12 µM:3 µM, and −47% for
16 µM:4 µM; p < 0.001 vs. vehicle). In contrast, miRNA-
218-5p expression was higher in PIs treated cells than in
the vehicle group (+220% for 12 µM:3 µM, and +81% for
16 µM:4 µM; respectively, p < 0.001 and p < 0.01 vs.
vehicle) (Figures 3A,B), confirming the existence of an inverse
relationship between lipin-1 and miRNA-218-5p expression in
fully differentiated 3T3-L1 cells.
Low Levels of Lipin-1 Correlate With
Lower Expression of GLUT-4 mRNA in
Mature 3T3-L1 Adipocytes
Since LPV:RTV treatment caused a reduction of lipin-1 mRNA
levels, we attempted to ascertain whether it correlated to reduced
levels of GLUT-4 mRNA in fully differentiated 3T3-L1. As
expected, we found significantly reduced levels of GLUT-4 mRNA
in LPV:RTV treated cells compared to vehicle treated cells (−74%
FIGURE 2 | Effect of LPV:RTV treatment on lipid accumulation. Fully
differentiated 3T3-L1 cells were treated as indicated in Figure 1. The
intracellular lipids were stained with Oil Red O; the absorbance was measured
at 520 nm. Absorbance was calculated as percent of that measured in vehicle
group. Results are expressed as mean ± SEM and represent the mean of 18
determinations obtained in three independent experiments. ∗p < 0.05 and
∗∗p < 0.01 vs. vehicle (A). Representative images for each treatment are
shown (B).
for 12 µM:3 µM and −57% for 16 µM:4 µM; respectively,
p< 0.01 and p< 0.05 vs. vehicle) (Figure 3C).
miRNA-218 Targets Lipin-1 mRNA and
Affects GLUT-4 Expression
The functional relevance of the specific miRNA/mRNA
interaction was validated. In order to ascertain whether miRNA-
218 could regulate lipin-1 mRNA, fully differentiated 3T3-L1 cells
treated with LPV/RTV 12 µM:3 µM for 48 h were transfected
with either specific inhibitors or mimics for miRNA-218-5p.
The efficiency of the miRNA inhibitor transfection was
evaluated by co-transfecting the cells with miRNA-let-7
inhibitor Positive Control, an endogenous miRNA that down-
regulates HMGA-2 gene expression. HMGA-2 is a ubiquitously
expressed non-histone chromatin protein that modulates gene
expression through changes in chromatin architecture. As
expected, transfection with miRNA-let-7 inhibitor significantly
increased the expression of HMGA-2 (+150% vs. negative
control; p < 0.01), attesting the efficacy of the adopted
procedure (Figure 4A).
Lipin-1 mRNA levels were significantly higher in cells treated
with PIs and miRNA-218 inhibitor compared to cells treated
with PIs and a scramble control miRNA (+ 34% vs. scrambled
control; p < 0.01). Conversely, mature adipocytes exposed to
LPV:RTV and transfected with a miRNA mimic of miRNA-
218 expressed lower levels of lipin-1 mRNA compared to cells
transfected with a scrambled miRNA (−22% for miRNA-218
mimic vs. scrambled control; p < 0.05) (Figure 4B). These
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FIGURE 3 | Effect of LPV:RTV treatment on lipin-1 and GLUT-4 mRNA
expression and miRNA-218 levels. Fully differentiated 3T3-L1 cells were
treated as indicated in the legend of Figure 1 levels of lipin-1 mRNA (A),
miRNA-218 (B) and GLUT-4 mRNA (C) were measured by real-time PCR.
Levels of lipin-1 and GLUT-4 mRNA were normalized by those of β-actin;
miRNA-218-5p levels were normalized using U6 levels. Values are the
mean ± SEM of 18 determinations per group obtained in three independent
experiments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. vehicle.
experiments clearly suggested a functional inverse relationship
between miRNA-218 and its putative target gene lipin-1.
GLUT-4 mRNA expression changed after treatment with
12 µM:3 µM PIs and concurrent transfection with either
miRNA 218-inhibitor or miRNA 218-mimic showing the same
trends observed for lipin-1. In fact, the miRNA-218 inhibitor
induced a significant increase of GLUT-4 mRNA levels (+17%
vs. scrambled; p< 0.05) whereas the miRNA-218 mimic lowered
them significantly (−12% vs. scrambled; p < 0.01) compared to
controls (Figure 4C).
Effects of Loss and Gain of Function of
miRNA-218 on Lipid Accumulation
The biological relevance of the loss of function of miRNA-218 in
3T3-L1 mature adipocytes was studied by measuring the effects
FIGURE 4 | miRNA-218 levels affect lipin-1 and GLUT-4 mRNA expression.
Fully differentiated 3T3-L1 cells treated with LPV:RTV (12 µM:3 µM) (PIs) for
48 h or with vehicle alone, were transfected with: (A) scrambled miRNA or
miRNA-let-7 inhibitor; (B,C) miRNA-218 inhibitor or miRNA-218 mimic or with
scrambled miRNA. mRNA levels of HMGA-2 (A) lipin-1 (B) and GLUT-4 (C)
were determined by real-time PCR 48 h after the transfection. Values are the
mean ± SEM of at least 18 determination obtained in three independent
experiments. ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. control (PIs+
scrambled miRNA).
of the transfection of a miRNA-218 inhibitor and a miRNA-218
mimic on lipid accumulation.
As expected, treatment with LPV:RTV 12 µM:3 µM caused a
significant decrease of lipid accumulation compared to control
cells (−9% PIs vs. vehicle; p < 0.05). Transfection with
scrambled miRNA did not affect lipid accumulation. Transfection
with the miRNA-218 mimic reduced the capability of 3T3-L1
cells to store lipid droplets (−10% PIs+ miRNA mimic vs.
vehicle; p < 0.05), without causing significant additive effects
compared to PIs alone. Conversely, inhibition of miRNA-218
activity by the specific miRNA inhibitor reversed PIs effects
and improved significantly the ability of the cells to store lipid
droplets (Figure 5).
Frontiers in Pharmacology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 461
fphar-10-00461 April 27, 2019 Time: 15:34 # 6
Bresciani et al. miRNA-218 Regulates Lipin-1 mRNA Levels
FIGURE 5 | Effects of loss and gain of function of miRNA-218 on lipid accumulation. Fully differentiated 3T3-L1 cells were treated with vehicle, or with PIs alone or in
combination with scrambled miRNA or miRNA-218 inhibitor or miRNA-218 mimic. The intracellular lipids were stained with Oil Red O; the absorbance was
measured at 520 nm and expressed as percent of control group. Results are the mean ± SEM of at least 18 determinations obtained in three independent
experiments. ∗p < 0.05 vs. vehicle.
DISCUSSION
Metabolic alterations and changes in the distribution of adipose
tissue are typical features of HIV-associated metabolic syndrome,
including LS, a serious problem occurring in patients taking anti-
HIV drugs. Since the pathophysiology of LS due to cART is
an irreversible process, even after drug withdrawal, elucidation
of the underlying mechanisms inducing LS is a matter of
particular importance (Finkelstein et al., 2015). LS was first
recognized in patients on PIs treatment (Carr and Cooper,
1998). PIs have revolutionized HIV treatment paradigms and
dramatically increased the life expectancy of the HIV-positive
population, although their administration is associated with
several adverse effects, including dyslipidaemia, insulin resistance
and hyperglycaemia (Holstein et al., 2001; Calza et al., 2004;
Calvo and Martinez, 2014). Among PI class, lopinavir boosted
with ritonavir, is frequently associated with metabolic disorders
(Calvo and Martinez, 2014). Recent guidelines for initial therapy
recommend use of integrase strand transfer inhibitors (INSTIs)
regimens in order to avoid the negative effects on metabolism.
However, PIs are currently part of cART especially in patients
harboring multi drug-resistant viruses (Huhn et al., 2017) and
exposure to ritonavir-boosted PIs is widely represented in
patients with a long history of treatment (Murnane et al., 2017).
Several studies have demonstrated alteration on adipocyte
differentiation and lipid content induced by PIs (Caron-
Debarle et al., 2010). It is known that in vitro LPV and RTV
activate endoplasmic reticulum (ER) stress in adipocytes
through proteasome inhibition, induce mitochondrial
dysfunction and ROS production, alter cell differentiation
and lipid content, and disrupt the expression of key
regulatory genes involved in lipid metabolism (Parker
et al., 2005; Capel et al., 2012; Zha et al., 2013). Indeed,
they interfere with intracellular processes regulating glucose
uptake in major insulin-responsive tissues. LPV/RTV
strongly inhibited glucose uptake by altering GLUT-4
activity in adipocytes (Giralt et al., 2006; Noor et al.,
2006). However, their precise effects in LS has been only
partially defined.
Altered miRNA processing and Dicer expression have been
proposed to have a role also in LS (Mori et al., 2014). In
this regards, exposure of the adipocytes to the PI saquinavir
resulted in upregulation of miRNAs, some of them have
been related to obesity, insulin resistance and lipolysis (Polus
et al., 2017); nevertheless, the functional significance of these
miRNAs is not defined.
To the best of our knowledge, this is the first research to
demonstrate (i) a direct link between the miRNA regulation
process in adipocytes and LPV/RTV treatment and (ii) a
functional relationship between a specific miRNA, the miRNA-
218 and its molecular target, the lipin-1 gene. Indeed, in
differentiated 3T3–L1 cells PIs treatment reduced lipin-1
mRNA expression and augmented miRNA-218 expression,
decreasing their capability to store lipid droplets. The “loss
and gain of function” studies allowed to demonstrate that
miRNA-218 targets the lipin-1 gene, thereby providing new
knowledge in the regulation of lipin-1 mRNA expression by
a specific miRNA.
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The interactions between a specific miRNA and its mRNA
target are difficult to assess. In this setting, “loss-of-function”
studies (in which a specific endogenous mature miRNA function
can be inhibited using antisense oligoribonucleotides), combined
with “gain of function” studies (in which a specific endogenous
mature miRNA function can be increased using an exogenous
miRNA mimic) constitute a validated and consolidated approach
(Kuhn et al., 2008). Beside the methodological procedure, it
is relevant the choice of the cell line. 3T3-L1 adipocytes and
SGBS pre-adipocytes are widespread used in vitro models for
providing detailed insights into the molecular mechanisms
governing adipogenesis (Capel et al., 2012; Zha et al., 2013;
Ahonen et al., 2019; Cave and Crowther, 2019). Although
3T3-L1 adipocytes have some limitations and could not be
completely representatives of in vivo conditions, they possess
some advantages: are homogenous in terms of cellular population
and their cells are all at the same differentiation stage, giving
a homogeneous response to treatments. For these reasons,
3T3-L1 have been widely utilized for in vitro studies of
anti-HIV drugs effects (Minami et al., 2011; Manente et al.,
2012; Parker et al., 2005) on growth and differentiation and
to investigate the role of different miRNAs in adipogenic
processes (Lin et al., 2009; Lee et al., 2011; Ahn et al., 2013;
Yun et al., 2015).
In differentiated 3T3-L1 cells exposed to different PIs
doses, the inhibition of miRNA-218 restored mRNA
levels of lipin-1 and allowed the recovery of adipogenic
functionality. By contrast, transfection of 3T3-L1 with the
miRNA-218-5p mimic had opposite effect, demonstrating that
miRNA-218 negatively regulates lipin-1 mRNA expression.
Analog approach has been utilized in other study where
the knockdown of miR-34a prevented the senescence of
vascular endothelial cells induced by LPV/RTV exposure (Zhan
et al., 2016). These results, consistent with those obtained in
subcutaneous adipose tissue of lipodystrophic HIV patients
on anti-HIV drugs (Squillace et al., 2014), namely miRNA-
218-5p over-expression and lipin-1 mRNA down-regulation,
corroborates the use of 3T3-L1 adipocytes treated with PIs
as a good in vitro model to investigate some open aspects of
lipodystrophy cART-induced.
To date, there is no report attesting a PIs direct effect
on miRNA-218 and lipin-1 mRNA expression. Lipin-1 has
been identified as a gene required for normal adipose
tissue development. It plays an essential role in adipocyte
differentiation and function (Peterfy et al., 2005; Sembongi
et al., 2013), and promotes C/EBPα and PPARγ2 gene
expression, which in turn controls the function of other
genes expressed in adipose tissue, as well as the fatty
acids binding protein 4 or phosphoenolpyruvate carboxykinase
(Chen et al., 2015). In addition to this role during early
adipogenesis, lipin-1 is also required for correct lipid droplet
biogenesis (Sembongi et al., 2013). Mutations of the lipin-
1 gene leads to LS in the mouse (Peterfy et al., 2001)
and adipocyte differentiation is completely blocked by siRNA-
mediated knock-down of lipin-1 (Chen et al., 2015). Both
lipin-1 expression levels in human adipose tissue and lipin-
1 genetic polymorphisms are associated with alterations in
body mass index and insulin sensitivity in different human
cohorts (Donkor et al., 2008; Wiedmann et al., 2008; Chang
et al., 2010). In contrast to the effects of lipin-1 deficiency,
selective overexpression of lipin-1 mRNA levels in adipocytes
induced obesity in transgenic mice, with increased size and
triglyceride content in adipocytes (Csaki and Reue, 2010).
Interestingly, the obese adipose-specific lipin-1 transgenic mice
were characterized by improved glucose and insulin homeostasis,
suggesting that increased capacity for triglyceride synthesis
within adipocytes via lipin-1 is metabolically favorable (Csaki
and Reue, 2010), perhaps by partitioning fatty acids into
adipose tissue and away from ectopic storage in other tissues
(Zhang and Reue, 2017).
HIV patients on cART regimens who are affected by
metabolic syndrome and lipodystrophy have decreased lipin-
1 mRNA expression in subcutaneous adipose tissue, compared
to HIV-infected patients without metabolic complications and
lipodystrophy. In addition, an inverse correlation between lipin-1
mRNA expression and miRNA-218 levels was observed (Squillace
et al., 2014). Nevertheless, until now the mechanisms underlying
this relationship has not been investigated.
The understanding of miRNA-218 role remains elusive; it
has been proposed as a tumor suppressor gene, and among its
targets have been recognized genes related to apoptosis, cellular
migration, tumor invasion and cellular proliferation (Yamamoto
et al., 2013; Yamasaki et al., 2013; Cao et al., 2015; Dong et al.,
2015; Han et al., 2015; Zhang et al., 2015).
A recent paper showed a relationship between miRNA-
218 and the function of GLUT (glucose transporter)-1 across
tumoral bladder cells: the overexpression of miRNA-218
could have contributed to decreased sensitivity of bladder
cancer cells to cisplatin by inhibiting GLUT-1 expression,
a key rate-limiting factor in the transport of glucose in
these cancer cells (Li et al., 2017). A primary feature
of insulin resistance in LS (Cortes and Fernandez-Galilea,
2015) is reduced GLUT-4 insulin-mediated glucose uptake in
muscle and adipose tissue (Gallego-Escuredo et al., 2013).
In muscle, this effect is mainly due to impaired recruitment
of GLUT-4 to the plasma membrane despite normal GLUT-
4 expression (Shepherd and Kahn, 1999); in adipocytes,
however, this effect seems to be associated with depressed
expression of GLUT-4 (Govers, 2014). Reduced levels of lipin-1
in mature adipocytes are linked to decreased expression of
GLUT-4 mRNA (Chen et al., 2015), the insulin-stimulated
glucose transporter specific for the adipocytes (Govers, 2014).
Given the relationship between miRNA-218 and lipin-1, we
speculated that miRNA-218 could also affect GLUT-4 gene
expression. Accordingly, we report for the first time that
LPV/RTV treatment reduces GLUT-4 mRNA expression in
differentiated 3T3-L1 cells and that, interestingly, this effect
is linked once again to miRNA-218 expression, as confirmed
by loss-of function studies. Consistent with our results,
also saquinavir influences gene expression of the GLUT-4
glucose transporter in adipocytes, inducing its down-regulation
(Polus et al., 2017).
In view of these outcomes, we hypothesize that the metabolic
alterations of adipose tissue observed in HIV patients could be
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ascribed to PIs effects on lipin-1 mRNA expression; this effect
is most likely indirectly mediated by an increase of miRNA-218
levels, as revealed by miRNA functional studies. These increased
miRNA-218 levels, indeed, negatively regulate lipin-1 mRNA
expression, causing alterations of his functionality. Increased
miRNA-218 levels could be also responsible for a reduced mRNA
expression of GLUT-4, suggesting that miRNA-218 could be
involved in the mechanisms by which cART induces metabolic
syndrome and insulin resistance in HIV patients.
In conclusion, the results of this study could help the
comprehension of mechanisms underlying the LS cART-induced
and open new perspectives of investigation.
AUTHOR CONTRIBUTIONS
EB wrote the manuscript and put the idea. EB, CS, LR, LM, and
RM conducted the study. EB, AT, NS, and VL helped to design
the study. EB, CS, and AT analyzed the data. RO, AG, GB, AT,
NS, and VL revised the manuscript.
FUNDING
This work was supported by Fondo di Ateneo per la Ricerca of
the University of Milano-Bicocca (FAR to AT and VL).
REFERENCES
Ahn, J., Lee, H., Jung, C. H., Jeon, T. I., and Ha, T. Y. (2013). MicroRNA-146b
promotes adipogenesis by suppressing the SIRT1-FOXO1 cascade. EMBO Mol.
Med. 5, 1602–1612. doi: 10.1002/emmm.201302647
Ahonen, M. A., Haridas, P. A. N., Mysore, R., Wabitsch, M., Fischer-Posovszky, P.,
and Olkkonen, V. M. (2019). mir-107 inhibits CDK6 expression, differentiation,
and lipid storage in human adipocytes. Mol. Cell. Endocrinol. 479, 110–116.
doi: 10.1016/j.mce.2018.09.007
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116, 281–297.
Calvo, M., and Martinez, E. (2014). Update on metabolic issues in HIV patients.
Curr. Opin. HIV AIDS 9, 332–339. doi: 10.1097/COH.0000000000000075
Calza, L., Manfredi, R., and Chiodo, F. (2004). Insulin resistance and diabetes
mellitus in HIV-infected patients receiving antiretroviral therapy. Metab. Syndr.
Relat. Disord. 2, 241–250. doi: 10.1089/met.2004.2.241
Cao, Q., Dong, P., Wang, Y., Zhang, J., Shi, X., and Wang, Y. (2015). miR-218
suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor
2D. Oncol. Rep. 33, 2606–2612. doi: 10.3892/or.2015.3861
Capel, E., Auclair, M., Caron-Debarle, M., and Capeau, J. (2012). Effects of
ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and
insulin sensitivity in murine and human adipocytes. Antivir. Ther. 17, 549–556.
doi: 10.3851/IMP1988
Caron-Debarle, M., Boccara, F., Lagathu, C., Antoine, B., Cervera, P., Bastard, J. P.,
et al. (2010). Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential
consequences on metabolic regulations. Curr. Pharm. Des. 16, 3352–3360.
doi: 10.2174/138161210793563446
Carr, A., and Cooper, D. A. (1998). Images in clinical medicine. lipodystrophy
associated with an HIV-protease inhibitor. N. Engl. J. Med. 339:1296. doi:
10.1056/nejm199810293391806
Cave, E., and Crowther, N. J. (2019). The use of 3T3-L1 murine preadipocytes as a
model of adipogenesis. Methods Mol. Biol. 1916, 263–272. doi: 10.1007/978-1-
4939-8994-2_25
Chang, Y. C., Chang, L. Y., Chang, T. J., Jiang, Y. D., Lee, K. C., Kuo, S. S.,
et al. (2010). The associations of LPIN1 gene expression in adipose tissue
with metabolic phenotypes in the Chinese population. Obesity 18, 7–12.
doi: 10.1038/oby.2009.198
Chen, Y., Rui, B. B., Tang, L. Y., and Hu, C. M. (2015). Lipin, family proteins–
key regulators in lipid metabolism. Ann. Nutr. Metab. 66, 10–18. doi: 10.1159/
000368661
Cortes, V. A., and Fernandez-Galilea, M. (2015). Lipodystrophies: adipose tissue
disorders with severe metabolic implications. J. Physiol. Biochem. 71, 471–478.
doi: 10.1007/s13105-015-0404-1
Costa, L. A., and Almeida, A. G. (2015). Cardiovascular disease associated with
human immunodeficiency virus: a review. Rev. Port. Cardiol. 34, 479–491.
doi: 10.1016/j.repc.2015.03.005
Croxtall, J. D., and Perry, C. M. (2010). Lopinavir/Ritonavir: a review of its use
in the management of HIV-1 infection. Drugs 70, 1885–1915. doi: 10.2165/
11204950-000000000-00000
Csaki, L. S., and Reue, K. (2010). Lipins: multifunctional lipid metabolism proteins.
Annu. Rev. Nutr. 30, 257–272. doi: 10.1146/annurev.nutr.012809.104729
Dong, Y., Zou, J., Su, S., Huang, H., Deng, Y., Wang, B., et al. (2015). MicroRNA-
218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in
hepatocellular carcinoma. Mol. Med. Rep. 12, 1016–1022. doi: 10.3892/mmr.
2015.3516
Donkor, J., Sparks, L. M., Xie, H., Smith, S. R., and Reue, K. (2008).
Adipose tissue lipin-1 expression is correlated with peroxisome proliferator-
activated receptor alpha gene expression and insulin sensitivity in healthy
young men. J. Clin. Endocrinol. Metab. 93, 233–239. doi: 10.1210/jc.2007-
1535
Finkelstein, J. L., Gala, P., Rochford, R., Glesby, M. J., and Mehta, S. (2015).
HIV/AIDS and lipodystrophy: implications for clinical management in
resource-limited settings. J. Int. AIDS Soc. 18:19033. doi: 10.7448/IAS.18.1.
19033
Gallego-Escuredo, J. M., Del Mar Gutierrez, M., Diaz-Delfin, J., Domingo, J. C.,
Mateo, M. G., Domingo, P., et al. (2010). Differential effects of efavirenz
and lopinavir/ritonavir on human adipocyte differentiation, gene expression
and release of adipokines and pro-inflammatory cytokines. Curr. HIV Res. 8,
545–553. doi: 10.2174/157016210793499222
Gallego-Escuredo, J. M., Villarroya, J., Domingo, P., Targarona, E. M., Alegre,
M., Domingo, J. C., et al. (2013). Differentially altered molecular signature
of visceral adipose tissue in HIV-1-associated lipodystrophy. Acquir. Immune
Defic. Syndr. 1, 142–148. doi: 10.1097/QAI.0b013e31829bdb67
Gibellini, L., De Biasi, S., Pinti, M., Nasi, M., Riccio, M., Carnevale, G., et al. (2012).
The protease inhibitor atazanavir triggers autophagy and mitophagy in human
preadipocytes. AIDS 26, 2017–2026. doi: 10.1097/QAD.0b013e328359b8be
Giralt, M., Domingo, P., Guallar, J. P., Rodriguez de la Concepciòn, P. L., Alegre,
M., Domingo, J. C., et al. (2006). HIV-1 infection alters gene expression in
adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy.
Antivir. Ther. 11, 729–740.
Govers, R. (2014). Molecular mechanisms of GLUT4 regulation in adipocytes.
Diabetes Metab. 40, 400–410. doi: 10.1016/j.diabet.2014.01.005
Han, G., Fan, M., and Zhangmicro, X. (2015). RNA-218 inhibits prostate cancer
cell growth and promotes apoptosis by repressing TPD52 expression. Biochem.
Biophys. Res. Commun. 456, 804–809. doi: 10.1016/j.bbrc.2014.12.026
Holstein, A., Plaschke, A., and Egberts, E. H. (2001). Lipodystrophy and metabolic
disorders as complication of antiretroviral therapy of HIV infection. Exp. Clin.
Endocrinol. Diabetes 109, 389–392. doi: 10.1055/s-2001-18990
Huhn, G. D., Tebas, P., Gallant, J., Wilkin, T., Cheng, A., Yan, M.,
et al. (2017). A randomized, open-label trial to evaluate switching to
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in
treatment-experienced hiv-1-infected adults. J. Acquir. Immune Defic. Syndr.
74, 193–200. doi: 10.1097/QAI.0000000000001193
Koh, Y. K., Lee, M. Y., Kim, J. W., Kim, M., Moon, J. S., Lee,
Y. J., et al. (2008). Lipin1 is a key factor for the maturation
and maintenance of adipocytes in the regulatory network with
CCAAT/enhancer-binding protein alpha and peroxisome proliferator-
activated receptor gamma 2. J. Biol. Chem. 283, 34896–34906.
doi: 10.1074/jbc.M804007200
Kuhn, D. E., Martin, M. M., Feldman, D. S. Jr., Terry, A. V., Nuovo, G. J., and Elton,
T. S. (2008). Experimental validation of miRNA targets. Methods 44, 47–54.
doi: 10.1016/j.ymeth.2007.09.005
Frontiers in Pharmacology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 461
fphar-10-00461 April 27, 2019 Time: 15:34 # 9
Bresciani et al. miRNA-218 Regulates Lipin-1 mRNA Levels
Kumar, G. N., Jayanti, V. K., Johnson, M. K., Uchic, J., Thomas, S., Lee, R. D., et al.
(2004). Metabolism and disposition of the HIV-1 protease inhibitor lopinavir
(ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Pharm. Res. 21, 1622–1630. doi: 10.1023/b:pham.0000041457.64638.8d
Lee, E. K., Lee, M. J., Abdelmohsen, K., Kim, W., Kim, M. M., Srikantan, S., et al.
(2011). miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-
activated receptor gamma expression. Mol. Cell Biol. 31, 626–638. doi: 10.1128/
MCB.00894-10
Li, P., Yang, X., Cheng, Y., Zhang, X., Yang, C., Deng, X., et al. (2017). MicroRNA-
218 increases the sensitivity of bladder cancer to cisplatin by targeting glut1.
Cell. Physiol. Biochem. 41, 921–932. doi: 10.1159/000460505
Lin, Q., Gao, Z., Alarcon, R. M., Ye, J., and Yun, Z. (2009). A role of miR-27 in the
regulation of adipogenesis. FEBS J. 276, 2348–2358.
Manente, L., Lucariello, A., Costanzo, C., Viglietti, R., Parrella, G., Parrella, R.,
et al. (2012). Suppression of pre adipocyte differentiation and promotion of
adipocyte death by anti-HIV drugs. In Vivo 26, 287–291.
Minami, R., Yamamoto, M., Takahama, S., Ando, H., Miyamura, T., and Suematsu,
E. (2011). Comparison of the influence of four classes of HIV antiretrovirals
on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.
J. Infect. Chemother. 17, 183–188. doi: 10.1007/s10156-010-0101-5
Mori, M. A., Thomou, T., Boucher, J., Lee, K. Y., Lallukka, S., Kim, J. K.,
et al. (2014). Altered miRNA processing disrupts brown/white adipocyte
determination and associates with lipodystrophy. J. Clin. Invest. 124, 3339–
3351. doi: 10.1172/JCI73468
Murnane, P. M., Strehlau, R., Shiau, S., Patel, F., Mbete, N., Hunt, G., et al.
(2017). Switching to efavirenz versus remaining on ritonavir-boosted lopinavir
in human immunodeficiency virus-infected children exposed to nevirapine:
long-term outcomes of a randomized trial. Clin. Infect. Dis. 65, 477–485.
doi: 10.1093/cid/cix335
Noor, M. A., Flint, O. P., Maa, J., and Parker, R. A. (2006). Effects of
atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin
sensitivity: demonstrable differences in vitro and clinically. AIDS 20, 1813–
1821. doi: 10.1097/01.aids.0000244200.11006.55
Parker, R. A., Flint, O. P., Mulvey, R., Elosua, C., Wang, F., Fenderson, W.,
et al. (2005). Endoplasmic reticulum stress links dyslipidemia to inhibition of
proteasome activity and glucose transport by HIV protease inhibitors. Mol.
Pharmacol. 67, 1909–1919. doi: 10.1124/mol.104.010165
Peterfy, M., Phan, J., and Reue, K. (2005). Alternatively spliced lipin isoforms
exhibit distinct expression pattern, subcellular localization, and role in
adipogenesis. J. Biol. Chem. 280, 32883–32889. doi: 10.1074/jbc.m503885200
Peterfy, M., Phan, J., Xu, P., and Reue, K. (2001). Lipodystrophy in the fld mouse
results from mutation of a new gene encoding a nuclear protein, lipin. Nat.
Genet. 27, 121–124. doi: 10.1038/83685
Polus, A., Bociaga-Jasik, M., Czech, U., Goralska, J., Cialowicz, U., Chojnacka, M.,
et al. (2017). The human immunodeficiency virus (HIV1) protease inhibitor
sanquinavir activates autophagy and removes lipids deposited in lipid droplets.
J. Physiol. Pharmacol. 68, 283–293.
Reinsch, N., Neuhaus, K., Esser, S., Potthoff, A., Hower, M., Mostardt, S.,
et al. (2012). German competence network heart failure; german competence
network for HIV/AIDS, Are HIV patients undertreated? cardiovascular risk
factors in HIV: results of the HIV-heart study. Eur. J. Prev. Cardiol. 19, 267–274.
doi: 10.1177/1741826711398431
Sembongi, H., Miranda, M., Han, G. S., Fakas, S., Grimsey, N., Vendrell, J., et al.
(2013). Distinct roles of the phosphatidate phosphatases lipin 1 and 2 during
adipogenesis and lipid droplet biogenesis in 3T3-L1 cells. J. Biol. Chem. 288,
34502–34513. doi: 10.1074/jbc.M113.488445
Shepherd, P. R., and Kahn, B. B. (1999). Glucose transporters and insulin action–
implications for insulin resistance and diabetes mellitus. N. Engl. J. Med. 341,
248–257. doi: 10.1056/nejm199907223410406
Squillace, N., Bresciani, E., Torsello, A., Bandera, A., Sabbatini, F., Giovannetti, C.,
et al. (2014). Changes in subcutaneous adipose tissue microRNA expression in
HIV-infected patients. J. Antimicrob. Chemother. 69, 3067–3075. doi: 10.1093/
jac/dku264
van Harmelen, V., Ryden, M., Sjolin, E., and Hoffstedt, J. (2007). A role of lipin in
human obesity and insulin resistance: relation to adipocyte glucose transport
and GLUT4 expression. J. Lipid. Res. 48, 201–206. doi: 10.1194/jlr.m600272-
jlr200
Wiedmann, S., Fischer, M., Koehler, M., Neureuther, K., Riegger, G., Doering,
A., et al. (2008). Genetic variants within the LPIN1 gene, encoding lipin, are
influencing phenotypes of the metabolic syndrome in humans. Diabetes Metab.
Res. Rev. 57, 209–217. doi: 10.2337/db07-0083
Xu, D., and Sun, L. (2015). Role of microRNA biogenesis in adipocyte and
lipodystrophy. Adipocyte 4, 222–224. doi: 10.1080/21623945.2014.995507
Yamamoto, N., Kinoshita, T., Nohata, N., Itesako, T., Yoshino, H., Enokida,
H., et al. (2013). Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion by targeting focal adhesion pathways in cervical
squamous cell carcinoma. Int. J. Oncol. 42, 1523–1532. doi: 10.3892/ijo.2013.
1851
Yamasaki, T., Seki, N., Yoshino, H., Itesako, T., Hidaka, H., Yamada, Y.,
et al. (2013). MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J. Urol. 190, 1059–1068. doi: 10.1016/j.juro.2013.
02.089
Yun, U. J., Song, N. J., Yang, D. K., Kwon, S. M., Kim, K., Kim, S., et al. (2015).
miR-195a inhibits adipocyte differentiation by targeting the preadipogenic
determinator Zfp423. J. Cell. Biochem. 116, 2589–2597. doi: 10.1002/jcb.25204
Zha, B. S., Wan, X., Zhang, X., Zha, W., Zhou, J., Wabitsch, M., et al. (2013).
HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic
reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One
8:e59514. doi: 10.1371/journal.pone.0059514
Zhan, J., Qin, S., Lu, L., Hu, X., Zhou, J., Sun, Y., et al. (2016). miR-34a is a common
link in both HIV- and antiretroviral therapy-induced vascular aging. Aging 8,
3298–3310. doi: 10.18632/aging.101118
Zhang, P., and Reue, K. (2017). Lipin proteins and glycerolipid metabolism: roles
at the ER membrane and beyond. Biochim. Biophys. Acta Biomembr. 1859,
1583–1595. doi: 10.1016/j.bbamem.2017.04.007
Zhang, X., Shi, H., Tang, H., Fang, Z., Wang, J., and Cui, S. (2015). miR-218
inhibits the invasion and migration of colon cancer cells by targeting the
PI3K/Akt/mTOR signaling pathway. Int. J. Mol. Med. 35, 1301–1308. doi: 10.
3892/ijmm.2015.2126
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Bresciani, Saletti, Squillace, Rizzi, Molteni, Meanti, Omeljaniuk,
Biagini, Gori, Locatelli and Torsello. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 461
